Last updated: February 14, 2026
Market Analysis and Price Projections for NDC 31722-0855
Product Overview
NDC 31722-0855 corresponds to Ruxolitinib (brand: Jakafi), a Janus kinase (JAK) inhibitor used primarily for myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. Approved by the FDA in 2011, it is marketed by Incyte Corporation.
Market Size and Growth
Market Drivers
- Rising prevalence of myeloproliferative disorders globally.
- Increased diagnosis rates due to advanced testing techniques.
- Expanded indications post-2017, including steroid-refractory graft-versus-host disease.
Global Market Forecast
- The global JAK inhibitor market was valued at approximately \$3 billion in 2022.
- Ruxolitinib accounts for around 60% of this market, with an estimated revenue of \$1.8 billion in 2022.
- Compound annual growth rate (CAGR) projected at 8% from 2023 to 2030, driven by new indications and increasing patient base.
Regional Insights
- North America: Dominates with over 70% of sales, supported by high diagnosis rates and reimbursement policies.
- Europe: Growth mirrors North America, with expansion in emerging markets.
- Asia-Pacific: Rapid adoption, expected to grow at a CAGR of 12%, due to expanding healthcare infrastructure.
Competition Landscape
Key Competitors
- Fedratinib (Incyte): Approved in 2019, targeting patients resistant or intolerant to ruxolitinib.
- Momelotinib (Gilead): Under clinical development for myelofibrosis.
- Pacritinib (CTI BioPharma): Approved for specific patient populations.
Market Share
- Ruxolitinib holds approximately 85% of the current JAK inhibitor market.
- Competition introduces pressure on pricing and market share growth.
Pricing Analysis
Current Pricing
- List Price: Approximately \$13,600 per month for a standard 10 mg twice-daily dose (source: Incyte).
- Net Price: Estimated to be 25-30% lower after discounts, rebates, and insurance negotiations.
Pricing Trends
- Price stability observed since initial launch in 2011.
- Slight adjustments may occur due to inflationary pressures and competitive dynamics.
Reimbursement and Payer Policies
- High reimbursement rates in the US; coverage varies in international markets.
- Payers favor the drug due to its efficacy and regulatory approval status.
Future Price Projections
Factors Influencing Future Prices
- Entry of generics or biosimilars typically decreases prices over time. Patent expiration for Ruxolitinib is expected around 2029.
- Early-stage negotiations and formulary placements impact actual costs.
- Development of alternative treatments could suppress prices.
Predicted Trends
- Over the next 5 years, list prices are unlikely to increase significantly.
- Discounting strategies and patent expirations may lead to a 15-25% reduction in net prices by 2030.
- International markets may see variance based on pricing regulations.
Patent and Regulatory Outlook
- Patent expiry in 2029 provides potential for generic competition.
- Regulatory approvals in additional indications (e.g., Covid-related cytokine storm) could extend market coverage, maintaining revenue levels despite price pressures.
Summary of Key Data and Projections
| Aspect |
Data |
Projection |
| Market size 2022 |
\$1.8 billion (Ruxolitinib) |
Maintains dominance through 2030 |
| CAGR (2023-2030) |
8% |
Market expansion persists |
| Price (US) |
\$13,600/month |
Stable initially, likely to decrease 15-25% by 2030 due to generics |
| Patent expiry |
2029 |
Potential influx of generics from 2029 onward |
Key Takeaways
- NDC 31722-0855 (Ruxolitinib) maintains a significant market share within JAK inhibitors, with a stable but mature pricing landscape.
- Market growth driven by increased diagnosis, expanded indications, and regional economic expansion.
- Price erosion expected after patent expiry in 2029, with potential reductions of 15-25% over the subsequent decade.
- Competition from emerging JAK inhibitors remains a factor but is currently limited in impact.
- Reimbursement policies and generic entry will influence net revenues and pricing strategies moving forward.
FAQs
1. When is patent expiry expected for Ruxolitinib?
Patent expiration is projected around 2029, opening the market to generics.
2. What is the current list price for Ruxolitinib?
Approximately \$13,600 per month in the US, with net prices likely 25-30% lower after negotiations.
3. How competitive is the market for JAK inhibitors?
Ruxolitinib dominates with about 85% market share; competitors are emerging but hold smaller portions.
4. What factors could affect future pricing?
Patent expiry, market entry of biosimilars/generics, new indications, and insurance coverage policies.
5. What is the forecasted market growth rate for Ruxolitinib?
Estimated CAGR of 8% from 2023 to 2030, supported by expanding indications and increased diagnosis rates.
Sources
[1] Incyte Corporation. Jakafi prescribing information.
[2] EvaluatePharma. World Preview 2022.
[3] MarketWatch. JAK inhibitors market analysis.
[4] FDA approvals and patent databases.
